Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference

SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Cowen and Company 38th Annual Health Care Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, March 13, 2018 at 11:20 a.m. ET / 8:20 a.m. PT. The conference will be held from March 12-14, 2018 in Boston.

A live audio webcast of the presentation will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura's pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company's website at www.kuraoncology.com.

Contacts

Pete De Spain

Vice President, Investor Relations &

Corporate Communications

Kura Oncology, Inc.

(858) 500-8803

pete@kuraoncology.com

Robert H. Uhl

Managing Director

Westwicke Partners, LLC

(858) 356-5932

robert.uhl@westwicke.com